Composition for the treatment of damaged tissue
AssigneePfizer Inc.
InventorsKevin Neil Dack, Michael John Davies, Paul Vincent Fish, Jonathan Paul Huggins, Fraser Stuart McIntosh, Nicholas Laurence Occleston
Life of this patent
Estimating the term…
Abstract
A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
Claims29
A pharmaceutical comprising a composition which comprises:
- (a) a growth factor;
- and
- (b) an inhibitor agent;
- and optionally
- (c) a pharmaceutically acceptable carrier, diluent or excipient;
- wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound environment.
A process for preparing a pharmaceutical for use in treating damaged tissue, such as a wound;
- the process comprising forming a composition by admixing (a) a growth factor with (b) an inhibitor agent;
- and (c) optionally also admixing with a pharmaceutically acceptable carrier, diluent or excipient;
- wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
A pack comprising at least two compartments;
- wherein first of said compartments houses a growth factor;
- and wherein second of said compartments houses an inhibitor agent, wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
A pharmaceutical comprising:
- (a) a growth factor;
- (b) an i:UPA and/or an iMMP;
- and optionally
- (c) a pharmaceutically acceptable carrier, diluent or excipient;
- wherein the iUPA and/or the iMMP can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
A pharmaceutical composition comprising:
- (i) an i:UPA
- (ii) an iMMP;
- and optionally
- (iii) a pharmaceutically acceptable carrier, diluent or excipient;
- wherein the iUPA and/or the iMMP can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
The invention according to any one of the preceding claims wherein the inhibitor is at least an i:UPA.
The invention according to any one of the preceding claims wherein the inhibitor is at least an i:MMP;
- wherein said MMP is MMP 3 and/or MMP 13.
Dependencies are inferred from the claim text.